论文部分内容阅读
目的:评价2007～2009年南京地区前列腺增生症治疗药物的应用情况及趋势。方法:回顾性分析2007～2009年南京地区前列腺增生症治疗药物的种类、用量、销售金额、用药频度、日均费用等项目。结果:用药总金额为6 329.15万元,进口及合资药物金额占71.48%,DDDs分析中居前的以激素类药物及相关酶抑制药为主。结论:前列腺增生症治疗药物用药金额呈增长趋势,国产药物市场份额下降。
Objective: To evaluate the application and trends of benign prostatic hyperplasia in Nanjing from 2007 to 2009. Methods: The types, dosage, sales amount, frequency of medication, daily average cost and other items of benign prostatic hyperplasia in Nanjing from 2007 to 2009 were analyzed retrospectively. Results: The total amount of medication was 6,391,500 yuan, and the amount of imported and joint-venture drugs accounted for 71.48%. Among the DDDs, the top three were hormone drugs and related enzyme inhibitors. Conclusion: The amount of drugs for treating benign prostatic hyperplasia shows an increasing trend, and the market share of domestic drugs declines.